CLL cells were treated with NECA, a stable adenosine receptor agonist, with or without exogenous IL-10 and IFN-γ, which have been shown to modulate PD-L1 expression on CLL [24,25]. This evidence concerns the gene IFNG and B-cell chronic lymphocytic leukemia.